Drugs / VIMNERIXIN
Trials 6
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT04105959 | Jul → Nov 2019 | inflammatory disease | Aristea Therapeutics, Inc. | Completed | No outcome recorded |
| Phase 1 | NCT01962935 | Nov 2013 → Jun 2014 | chronic obstructive pulmonary disease | AstraZeneca | Completed | No outcome recorded |
| Phase 24 trials · 1 missed | ||||||
| Phase 2 | NCT05448391 | Sep 2022 → Nov 2023 | familial Mediterranean fever | Aristea Therapeutics, Inc. | Withdrawn | No outcome recorded |
| Phase 2 | NCT05348681 | Jul 2022 → Feb 2023 | hidradenitis suppurativa | Aristea Therapeutics, Inc. | Terminated | No outcome recorded |
| Phase 2 | NCT05194839 | Jan 2022 → Feb 2023 | palmoplantar pustulosis | Aristea Therapeutics, Inc. | Terminated | No outcome recorded |
| Phase 2 | NCT03988335 | Feb → Nov 2019 | palmoplantar pustulosis | Aristea Therapeutics, Inc. | Completed | Missed primary |
| Comparator or background therapy1 trial | ||||||
| Phase 1 | NCT01889160 Comparator | Jul → Dec 2013 | — | AstraZeneca | Completed | No outcome recorded |
Evidence & citations 9 cited values
Every value below carries the sentence it was read from. 9 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | VIMNERIXIN | ChEMBL registry synonym — accepted as the source's own label CHEMBL5095217 ↗ |
| Known as | AZD4721 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01962935 ↗ |
| Known as | RIST4721 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03988335 ↗ |
| Known as | Vimnerixina | ChEMBL registry synonym — accepted as the source's own label CHEMBL5095217 ↗ |
| Known as | Vimnerixine | ChEMBL registry synonym — accepted as the source's own label CHEMBL5095217 ↗ |
| Action | Inhibit | “RIST4721 antagonizes CXC chemokine receptor type 2” PMID 34716902 ↗ Oct 2021 |
| Modality | Small molecule | — CHEMBL5095217 ↗ |
| Route | Oral | “Oral AZD4721 Solution” NCT01889160 ↗ |
| Target | CXCR2 | “RIST4721, a Novel CXCR2 Inhibitor” NCT04105959 ↗ |